XTalks

FEBRUARY 4, 2021

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Biobanking will continue to play an integral role in accelerating drug discovery and development, which will necessitate access to a larger array of biological samples.

Research 98

Research Biobanking Drugs Genome 98

Bioengineer

JANUARY 16, 2024

Often, the loss of T790M is associated with the development of alternative competitive resistance mechanisms. Another genetic change at the C797 residue in the ATP binding region of EGFR’s exon 20 has emerged as a key mechanism of resistance to osimertinib. Reported changes include L718Q and L718V.

Genome 119

Genome Genomics Protein In-Vitro 119

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

Drugs 52

Drugs Genotype Bioavailability Medicine 52

The Pharma Data

NOVEMBER 2, 2020

(NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today provided an update on its landmark ONWARD Phase 3 pivotal trial. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions.

Trials 52

Trials Genotype Marketing Production 52

The Pharma Data

MARCH 7, 2022

Food and Drug Administration announced it has made a low-risk determination for the marketing of products, including food, from two genome-edited beef cattle and their offspring after determining that the intentional genomic alteration (IGA) does not raise any safety concerns (low-risk determination). The FDA, an agency within the U.S.

Genome 52

Genome Genomics Production Marketing 52

XTalks

MARCH 3, 2021

The US Food and Drug Administration (FDA) has granted approval to Nulibry (fosdenopterin) for reducing the risk of death associated with molybdenum cofactor deficiency type A (MoCD Type A), making it the first treatment for the ultra-rare, genetic metabolic disorder. The approval was granted to BridgeBio Pharma, Inc.

FDA Approval 64

FDA Approval Genotype Clinical Trials Clinical Trials 64

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

The Pharma Data

NOVEMBER 18, 2020

HIV drug resistance is caused by changes in the genetic structure of HIV that affects the ability of drugs to block the replication of the virus. Minimizing the emergence and transmission of HIV drug resistance is a vital part of global. WHO has developed survey methods to monitor pretreatment HIV drug resistance.

Drugs 52

Drugs Genotype Medicine Development 52

XTalks

APRIL 24, 2023

Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. Last year, the FDA approved five novel cellular and gene therapy products with orphan drug designation. Rare diseases can often be progressive, chronic and fatal.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

XTalks

DECEMBER 12, 2023

“In some areas, say Alzheimer’s disease, we have growing collections of imaging, gene, cerebrospinal fluid (CSF) and blood markers to follow and look at target engagement of our drugs,” says James Vornov, MD, PhD, Vice President of the Medical Department at Medpace. Furthermore, blood NfL has shown its versatility as a biomarker.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

The Pharma Data

DECEMBER 9, 2020

Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. It will if the following five companies, which all launched this year with Series A financing, have anything to say about it. . Vigil Neuroscience.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

Pharmaceutical Technology

AUGUST 18, 2022

The US Food and Drug Administration (FDA) has granted approval for bluebird bio ’s Zynteglo (betibeglogene autotemcel, beti-cel) for the treatment of the underlying genetic cause of beta?thalassemia 0 genotypes. thalassemia in adult and paediatric patients.

Gene Therapy 246

Gene Therapy Gene Genotype Genetics 246

Delveinsight

DECEMBER 16, 2020

Further, diagnostics and screening, poverty, the stigma associated with the STDs, younger patient pool, illicit drug & alcohol use and negligence are some of the other key factors attributing to the increasing burden of STDs. A number of antiretroviral drugs are available in the market today, that can be combined in different ways.

Bacteria 52

Bacteria Development Genotype Vaccination 52

Drug Discovery World

MARCH 1, 2023

Avtar Singh is a Senior Scientist in the Cell and Tissue Genomics Department at Genentech, where he develops new approaches for image-based screening and high-throughput biological discovery. DDW’s Megan Thomas spoke with Singh about SLAS2023, where he presented Image-based screening of pooled genetic libraries.

Genetics 52

Genetics Genome Genomics Genotype 52

Drug Discovery World

OCTOBER 30, 2023

RA: You’ve recently announced a collaboration with the University of Oxford to access genotype data on women with endometriosis. We previously conducted a hypothesis-free study using genotype data from the UK Biobank, which resulted in the first mechanism-based stratification of endometriosis patients.

Genome 72

Genome Genomics Genotype Clinical Trials 72

Drug Discovery World

DECEMBER 12, 2023

Selecting a development candidate for our AATD program is an important milestone for Korro, but more importantly, for patients. I look forward to having access to this therapy as quickly as possible.” The post RNA editing oligonucleotide selected for AATD treatment appeared first on Drug Discovery World (DDW).

RNA 52

RNA In-Vivo Genotype Genetics 52

The Pharma Data

NOVEMBER 24, 2020

Food and Drug Administration (FDA) approved Oxlumo (lumasiran) injection for subcutaneous use, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare genetic disease characterized by oxalate overproduction.

FDA Approval 52

FDA Approval Production RNA Medicine 52

pharmaphorum

FEBRUARY 17, 2022

Researchers discovered a highly virulent variant of HIV in the Netherlands that genetic sequence analysis suggests has been circulating since the 1990s. . Identified as the “VB variant,” the virus has proved to be highly virulent and to speed up the progression of a patient developing AIDS faster. Effects of the variant.

Genome 98

Genome Genomics Genetics Genotype 98